180 related articles for article (PubMed ID: 21459953)
1. Immunologic reconstitution after rituximab in systemic lupus erythematosus: why should we care?
Anolik J
J Rheumatol; 2011 Apr; 38(4):587-9. PubMed ID: 21459953
[No Abstract] [Full Text] [Related]
2. Rituximab - shadow, illusion or light?
van Vollenhoven RF
Autoimmun Rev; 2012 Jun; 11(8):563-7. PubMed ID: 22036829
[TBL] [Abstract][Full Text] [Related]
3. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: Two sides of the same coin.
Conti F; Perricone C; Ceccarelli F; Valesini G
Autoimmun Rev; 2010 Sep; 9(11):716-20. PubMed ID: 20667484
[No Abstract] [Full Text] [Related]
4. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
[TBL] [Abstract][Full Text] [Related]
5. B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE.
Iwata S; Saito K; Tokunaga M; Tanaka Y
Ann Rheum Dis; 2012 Oct; 71(10):1749-50. PubMed ID: 22586167
[No Abstract] [Full Text] [Related]
6. Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus.
Faria RM; Isenberg DA
Lupus; 2010 Sep; 19(10):1256-7. PubMed ID: 20534646
[No Abstract] [Full Text] [Related]
7. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus.
Catapano F; Chaudhry AN; Jones RB; Smith KG; Jayne DW
Nephrol Dial Transplant; 2010 Nov; 25(11):3586-92. PubMed ID: 20466686
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-it was the best of times, it was the worst of times.
Isenberg DA
Autoimmun Rev; 2012 Sep; 11(11):790-1. PubMed ID: 22349619
[TBL] [Abstract][Full Text] [Related]
9. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study.
Pego-Reigosa JM; Lu TY; Fontanillo MF; del Campo-Pérez V; Rahman A; Isenberg DA
Rheumatology (Oxford); 2010 Apr; 49(4):691-6. PubMed ID: 20047982
[TBL] [Abstract][Full Text] [Related]
10. Persistent memory B cell down-regulation after 6-year remission induced by rituximab therapy in patients with systemic lupus erythematosus.
Iwata S; Saito K; Tokunaga M; Tanaka Y
Lupus; 2013 Apr; 22(5):538-40. PubMed ID: 23423251
[No Abstract] [Full Text] [Related]
11. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience.
Lateef A; Lahiri M; Teng GG; Vasoo S
Lupus; 2010 May; 19(6):765-70. PubMed ID: 20118162
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in lupus and beyond: the state of the art.
Hughes G
Lupus; 2009 Jun; 18(7):639-44. PubMed ID: 19433465
[No Abstract] [Full Text] [Related]
13. Complement C2 deficiency disarranging innate and adaptive humoral immune responses in a pediatric patient: treatment with rituximab.
Hauck F; Lee-kirsch MA; Aust D; Roesler J; Pessler F
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):454-9. PubMed ID: 20890976
[No Abstract] [Full Text] [Related]
14. [B-lymphocytes as effectors and regulators in systemic lupus erythematosus].
Winkler TH
Z Rheumatol; 2014 May; 73(4):360-2. PubMed ID: 24722870
[No Abstract] [Full Text] [Related]
15. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide.
Gupta RK; Ezeonyeji AN; Thomas AS; Scully MA; Ehrenstein MR; Isenberg DA
Lupus; 2011 Dec; 20(14):1547-50. PubMed ID: 21993386
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in the treatment of bullous systemic lupus erythematosus.
Alsanafi S; Kovarik C; Mermelstein AL; Werth VP
J Clin Rheumatol; 2011 Apr; 17(3):142-4. PubMed ID: 21441817
[TBL] [Abstract][Full Text] [Related]
17. [Anti-CD20 antibody therapy for inflammatory immune diseases].
Tanaka Y
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1801-6. PubMed ID: 17037318
[No Abstract] [Full Text] [Related]
18. [Molecular targets and their regulation in systemic lupus erythematosus and lupus nephritis].
Takasaki Y
Nihon Jinzo Gakkai Shi; 2012; 54(5):598-602. PubMed ID: 22991839
[No Abstract] [Full Text] [Related]
19. Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Croca S; Gerona D; De La Torre I; Isenberg D; McDonald V; Leandro M; Cambridge G
Rheumatology (Oxford); 2013 May; 52(5):951-2. PubMed ID: 23424262
[No Abstract] [Full Text] [Related]
20. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
